Refractory Chylothorax and Ventricular Hypertrophy Treated with Trametinib in a Patient with Noonan Syndrome: 18-Month Follow-Up

RASopathies are a group of genetic syndromes caused by germline mutations in genes involved in the RAS/Mitogen-Activated Protein Kinase signaling pathway, which regulates cellular proliferation, differentiation, and angiogenesis. Despite their involvement at different levels of this pathway, RASopat...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Antonia Pascarella, Giuseppe Limongelli, Alessandro De Falco, Elia Marco Paolo Minale, Giangiacomo Di Nardo, Giovanni Maria Di Marco, Geremia Zito Marinosci, Giorgia Olimpico, Paolo Siani, Daniele De Brasi
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	MDPI AG 2024-10-01
سلاسل:	Children
الموضوعات:	Noonan syndrome targeted molecular therapy MEK inhibitor hypertrophic cardiomyopathy pulmonary stenosis refractory chylothorax
الوصول للمادة أونلاين:	https://www.mdpi.com/2227-9067/11/11/1342
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!